Author information:
(1)Philippe Armand and Edie Weller, Dana-Farber Cancer Institute; David E. 
Avigan, Beth Israel Deaconess Medical Center; Yi-Bin Chen, Massachusetts General 
Hospital, Boston, MA; Arnon Nagler, Chaim Sheba Medical Center, Tel-Hashomer; 
Reuven Or, Hadassah Medical Center, Jerusalem; Rinat Rotem-Yehudar, CureTech, 
Yavne, Israel; Steven M. Devine, The Ohio State University Comprehensive Cancer 
Center, Ohio State University, Columbus; Hillard M. Lazarus, Case Western 
Reserve University and University Hospitals Case Medical Center, Cleveland, OH; 
Mark S. Kaminski, University of Michigan, Ann Arbor, MI; H. Kent Holland, 
Northside Hospital; Edmund K. Waller, Winship Cancer Institute, Emory 
University, Atlanta, GA; Jane N. Winter and Leo I. Gordon, Robert H. Lurie 
Comprehensive Cancer Center, Northwestern University Feinberg School of 
Medicine; Stephanie A. Gregory, Rush Medical Center, Chicago, IL; James R. 
Mason, Scripps Clinic; Edward D. Ball, Moores University of California at San 
Diego Cancer Center, University of California, San Diego; John M. Timmerman and 
David Andorsky, University of California, Los Angeles, Los Angeles, CA; Joseph 
W. Fay, Baylor Research Institute, Baylor University Medical Center, Dallas; 
Chitra M. Hosing, The University of Texas MD Anderson Cancer Center, Houston, 
TX; David A. Rizzieri, Duke Cancer Center, Durham, NC; Joseph P. Uberti, 
Karmanos Cancer Institute, Detroit, MI; Markus Y. Mapara, University of 
Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA.